MAPT and early-onset autosomal dominant Alzheimer disease: A “proof of principle” of the power of that tau-3R labeling has been demonstrated showing modulation of tau-3R positive axons under physiological conditions (exercise and aging) and diverse neurodegenerative (FTDP-17 and Alzheimer disease) models.